Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use

[1]  M. Snyder,et al.  A DMS Shotgun Lipidomics Workflow Application to Facilitate High-Throughput, Comprehensive Lipidomics. , 2021, Journal of the American Society for Mass Spectrometry.

[2]  M. Orho-Melander,et al.  Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease , 2021, Journal of hepatology.

[3]  M. Inglot,et al.  ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials , 2021, Nature Medicine.

[4]  B. Neuschwander‐Tetri,et al.  TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. , 2021, Gastroenterology.

[5]  Ben Orsburn,et al.  Proteome Discoverer—A Community Enhanced Data Processing Suite for Protein Informatics , 2021, Proteomes.

[6]  D. Mozaffarian,et al.  Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. , 2020, JAMA.

[7]  Conrad C. Huang,et al.  UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.

[8]  C. Chi,et al.  Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis , 2020, Nutrients.

[9]  Baptiste N. Jaeger,et al.  FASN-Dependent Lipid Metabolism Links Neurogenic Stem/Progenitor Cell Activity to Learning and Memory Deficits. , 2020, Cell stem cell.

[10]  J. Borén,et al.  Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance , 2020, Nature Communications.

[11]  S. Tarabar,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study , 2020, Clinical pharmacology in drug development.

[12]  C. Postic,et al.  Carbohydrate Sensing Through the Transcription Factor ChREBP , 2019, Front. Genet..

[13]  Sungguan Hong,et al.  The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism , 2018, Journal of molecular cell biology.

[14]  R. Loomba,et al.  GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[15]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[16]  G. Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[17]  E. Barroso,et al.  Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus , 2017, Trends in Endocrinology & Metabolism.

[18]  S. Milstein,et al.  Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. , 2017, Cell metabolism.

[19]  A. Logan,et al.  Non-enzymatic N-acetylation of Lysine Residues by AcetylCoA Often Occurs via a Proximal S-acetylated Thiol Intermediate Sensitive to Glyoxalase II , 2017, Cell reports.

[20]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[21]  M. Orešič,et al.  Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[22]  J. Heeren,et al.  FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. , 2016, Cell metabolism.

[23]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[24]  S. Tsuji,et al.  Differential Effect of HDAC3 on Cytoplasmic and Nuclear Huntingtin Aggregates , 2014, PloS one.

[25]  H. Yin,et al.  Regulation of fatty acid composition and lipid storage by thyroid hormone in mouse liver , 2014, Cell & Bioscience.

[26]  K. Petersen,et al.  The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes , 2014, Nature.

[27]  U. Knippschild,et al.  De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health , 2013, Nature Communications.

[28]  J. Montani,et al.  A Role for Adipose Tissue De Novo Lipogenesis in Glucose Homeostasis During Catch-up Growth , 2013, Diabetes.

[29]  M. Uusitupa,et al.  Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. , 2012, The American journal of clinical nutrition.

[30]  Shelly C. Lu,et al.  Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. , 2012, Journal of proteome research.

[31]  A. Guillouzo,et al.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells , 2011, Hepatology.

[32]  G. Gores,et al.  Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. , 2010, Journal of hepatology.

[33]  S. Watkins,et al.  Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism , 2008, Cell.

[34]  Timm Maier,et al.  The Crystal Structure of a Mammalian Fatty Acid Synthase , 2008, Science.

[35]  S. Piro,et al.  Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[36]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[37]  G. Bedogni,et al.  Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[38]  M. Vidal,et al.  Role of histone H2A ubiquitination in Polycomb silencing , 2004, Nature.

[39]  H. Shimano,et al.  Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP‐1 suppression , 2003, Hepatology.

[40]  S. Chirala,et al.  Fatty acid synthesis is essential in embryonic development: Fatty acid synthase null mutants and most of the heterozygotes die in utero , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Shimano,et al.  A Crucial Role of Sterol Regulatory Element-binding Protein-1 in the Regulation of Lipogenic Gene Expression by Polyunsaturated Fatty Acids* , 1999, The Journal of Biological Chemistry.

[42]  G. Leveille,et al.  Significance of adipose tissue and liver as sites of fatty acid synthesis in the pig and the efficiency of utilization of various substrates for lipogenesis. , 1969, The Journal of nutrition.

[43]  S. Burks,et al.  Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. , 2015, Journal of hepatology.